Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer
Background Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil‐to‐lymphocyte ratio (NLR) kinetics could be used to predict the an...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2019-08, Vol.41 (8), p.2610-2618 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2618 |
|---|---|
| container_issue | 8 |
| container_start_page | 2610 |
| container_title | Head & neck |
| container_volume | 41 |
| creator | Yasumatsu, Ryuji Wakasaki, Takahiro Hashimoto, Kazuki Nakashima, Koichiro Manako, Tomomi Taura, Masahiko Matsuo, Mioko Nakagawa, Takashi |
| description | Background
Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil‐to‐lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab.
Patients and Methods
Forty‐one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment.
Results
The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76%) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91%) with stable disease or partial response during the follow‐up period.
Conclusion
Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy. |
| doi_str_mv | 10.1002/hed.25737 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2188588639</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2188588639</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-54781d543341c7171b35984a1c57e8f062b8e2a1fc2e9b72da769e688dade3b33</originalsourceid><addsrcrecordid>eNp1kU1u1jAQhiMEoqWw4ALIEhtYpPVv7CxRaSlSERtYW44zIS6JHWwHlF2PwBW4GifBJf02SGw8lufx47HeqnpO8CnBmJ6N0J9SIZl8UB0T3MoaMy4f3u05qxmW_Kh6ktINxpg1nD6ujhhWTLSkPa5-fQje5RCd_4LyCMjDmmNYRjf9vv2ZQ1mmbV7GYLcMKJrsAprNhjpAa4JhndAQIloi9M7mg8P47KzxFiKCYQCbURiQd9_DtM6mQ86jCHaNEXzpRDRDNikXtUUjmL5c78sY9ivaHU-rR4OZEjy7ryfV58uLT-dX9fXHd-_P31zXlgkma8GlIr3gjHFiJZGkKz9U3BArJKgBN7RTQA0ZLIW2k7Q3smmhUao3PbCOsZPq1e5dYvi2Qsp6dsnCNBkPYU2aEqWEUg1rC_ryH_QmrNGX6TSlQvDysBCFer1TNoaUIgx6iW42cdME67vcdMlN_82tsC_ujWs3l9MDeQiqAGc78MNNsP3fpK8u3u7KP-mTphI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2255459855</pqid></control><display><type>article</type><title>Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yasumatsu, Ryuji ; Wakasaki, Takahiro ; Hashimoto, Kazuki ; Nakashima, Koichiro ; Manako, Tomomi ; Taura, Masahiko ; Matsuo, Mioko ; Nakagawa, Takashi</creator><creatorcontrib>Yasumatsu, Ryuji ; Wakasaki, Takahiro ; Hashimoto, Kazuki ; Nakashima, Koichiro ; Manako, Tomomi ; Taura, Masahiko ; Matsuo, Mioko ; Nakagawa, Takashi</creatorcontrib><description>Background
Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil‐to‐lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab.
Patients and Methods
Forty‐one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment.
Results
The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76%) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91%) with stable disease or partial response during the follow‐up period.
Conclusion
Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.25737</identifier><identifier>PMID: 30835919</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>biomarker ; Cancer ; Head & neck cancer ; head and neck ; immune checkpoint inhibitor ; Immunotherapy ; Metastases ; Metastasis ; Monoclonal antibodies ; Neutrophils ; neutrophil‐to‐lymphocyte ratio ; Squamous cell carcinoma ; Targeted cancer therapy</subject><ispartof>Head & neck, 2019-08, Vol.41 (8), p.2610-2618</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-54781d543341c7171b35984a1c57e8f062b8e2a1fc2e9b72da769e688dade3b33</citedby><cites>FETCH-LOGICAL-c3537-54781d543341c7171b35984a1c57e8f062b8e2a1fc2e9b72da769e688dade3b33</cites><orcidid>0000-0001-6199-0341</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.25737$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.25737$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30835919$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yasumatsu, Ryuji</creatorcontrib><creatorcontrib>Wakasaki, Takahiro</creatorcontrib><creatorcontrib>Hashimoto, Kazuki</creatorcontrib><creatorcontrib>Nakashima, Koichiro</creatorcontrib><creatorcontrib>Manako, Tomomi</creatorcontrib><creatorcontrib>Taura, Masahiko</creatorcontrib><creatorcontrib>Matsuo, Mioko</creatorcontrib><creatorcontrib>Nakagawa, Takashi</creatorcontrib><title>Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil‐to‐lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab.
Patients and Methods
Forty‐one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment.
Results
The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76%) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91%) with stable disease or partial response during the follow‐up period.
Conclusion
Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.</description><subject>biomarker</subject><subject>Cancer</subject><subject>Head & neck cancer</subject><subject>head and neck</subject><subject>immune checkpoint inhibitor</subject><subject>Immunotherapy</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Neutrophils</subject><subject>neutrophil‐to‐lymphocyte ratio</subject><subject>Squamous cell carcinoma</subject><subject>Targeted cancer therapy</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kU1u1jAQhiMEoqWw4ALIEhtYpPVv7CxRaSlSERtYW44zIS6JHWwHlF2PwBW4GifBJf02SGw8lufx47HeqnpO8CnBmJ6N0J9SIZl8UB0T3MoaMy4f3u05qxmW_Kh6ktINxpg1nD6ujhhWTLSkPa5-fQje5RCd_4LyCMjDmmNYRjf9vv2ZQ1mmbV7GYLcMKJrsAprNhjpAa4JhndAQIloi9M7mg8P47KzxFiKCYQCbURiQd9_DtM6mQ86jCHaNEXzpRDRDNikXtUUjmL5c78sY9ivaHU-rR4OZEjy7ryfV58uLT-dX9fXHd-_P31zXlgkma8GlIr3gjHFiJZGkKz9U3BArJKgBN7RTQA0ZLIW2k7Q3smmhUao3PbCOsZPq1e5dYvi2Qsp6dsnCNBkPYU2aEqWEUg1rC_ryH_QmrNGX6TSlQvDysBCFer1TNoaUIgx6iW42cdME67vcdMlN_82tsC_ujWs3l9MDeQiqAGc78MNNsP3fpK8u3u7KP-mTphI</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Yasumatsu, Ryuji</creator><creator>Wakasaki, Takahiro</creator><creator>Hashimoto, Kazuki</creator><creator>Nakashima, Koichiro</creator><creator>Manako, Tomomi</creator><creator>Taura, Masahiko</creator><creator>Matsuo, Mioko</creator><creator>Nakagawa, Takashi</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6199-0341</orcidid></search><sort><creationdate>201908</creationdate><title>Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer</title><author>Yasumatsu, Ryuji ; Wakasaki, Takahiro ; Hashimoto, Kazuki ; Nakashima, Koichiro ; Manako, Tomomi ; Taura, Masahiko ; Matsuo, Mioko ; Nakagawa, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-54781d543341c7171b35984a1c57e8f062b8e2a1fc2e9b72da769e688dade3b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>biomarker</topic><topic>Cancer</topic><topic>Head & neck cancer</topic><topic>head and neck</topic><topic>immune checkpoint inhibitor</topic><topic>Immunotherapy</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Neutrophils</topic><topic>neutrophil‐to‐lymphocyte ratio</topic><topic>Squamous cell carcinoma</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yasumatsu, Ryuji</creatorcontrib><creatorcontrib>Wakasaki, Takahiro</creatorcontrib><creatorcontrib>Hashimoto, Kazuki</creatorcontrib><creatorcontrib>Nakashima, Koichiro</creatorcontrib><creatorcontrib>Manako, Tomomi</creatorcontrib><creatorcontrib>Taura, Masahiko</creatorcontrib><creatorcontrib>Matsuo, Mioko</creatorcontrib><creatorcontrib>Nakagawa, Takashi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yasumatsu, Ryuji</au><au>Wakasaki, Takahiro</au><au>Hashimoto, Kazuki</au><au>Nakashima, Koichiro</au><au>Manako, Tomomi</au><au>Taura, Masahiko</au><au>Matsuo, Mioko</au><au>Nakagawa, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2019-08</date><risdate>2019</risdate><volume>41</volume><issue>8</issue><spage>2610</spage><epage>2618</epage><pages>2610-2618</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><abstract>Background
Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil‐to‐lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab.
Patients and Methods
Forty‐one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment.
Results
The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76%) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91%) with stable disease or partial response during the follow‐up period.
Conclusion
Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>30835919</pmid><doi>10.1002/hed.25737</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6199-0341</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2019-08, Vol.41 (8), p.2610-2618 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2188588639 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | biomarker Cancer Head & neck cancer head and neck immune checkpoint inhibitor Immunotherapy Metastases Metastasis Monoclonal antibodies Neutrophils neutrophil‐to‐lymphocyte ratio Squamous cell carcinoma Targeted cancer therapy |
| title | Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T09%3A34%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monitoring%20the%20neutrophil%E2%80%90to%E2%80%90lymphocyte%20ratio%20may%20be%20useful%20for%20predicting%20the%20anticancer%20effect%20of%20nivolumab%20in%20recurrent%20or%20metastatic%20head%20and%20neck%20cancer&rft.jtitle=Head%20&%20neck&rft.au=Yasumatsu,%20Ryuji&rft.date=2019-08&rft.volume=41&rft.issue=8&rft.spage=2610&rft.epage=2618&rft.pages=2610-2618&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.25737&rft_dat=%3Cproquest_cross%3E2188588639%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2255459855&rft_id=info:pmid/30835919&rfr_iscdi=true |